Tucked inside the 1914 Mutual Building at 100 E. Fifth St., a new business has found its home. With the hope of enhancing wellness in North Platte, cousins and co-owners Jacque Stittle and Natasha ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced an exclusive licensing ...

Science has confirmed what sports lovers have always known from experience: exercise is good for the brain. It increases blood flow, inhibits stress hormones, and stimulates the release of 'feel good' ...

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years 1 Subcutaneous Lunsumio has potential to ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J., September 19, ...

At its September meeting, Europe’s Pharmacovigilance Risk Assessment Committee (PRAC) discussed a direct healthcare professional communication that will warn clinicians about the risk for severe ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...

The FDA confirmed the nationwide shortage of sodium chloride 0.9% injection, or IV saline, has officially ended. The IV saline shortage, which has affected hospitals and clinics across the country, is ...

- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, ...

- The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions ...